Diabetes injection pens are now more commonly used to administer oral diabetes medications to people who have difficulty swallowing. These pens allow the diabetics to inject themselves with a dose of their chosen oral diabetes medication. Insulin pumps and vial style pumps are often used for administering insulin shots and there are also single-dose vials that can be stored in a personal bag or small box and taken at a convenient time.
There are many different types of diabetes injection pens available from medical supply companies offering an array of options to the consumer. These are made of rubber latex or similar flexible material that is durable and resistant to infection. The needles are usually made of sterile stainless steel but rubber inserts are available for use with some units. Depending on what brand and type of diabetes medicine are being ordered, the pen will be embossed with the letter of the patient's first name, the word "diabetic" or another symbol indicating this fact and their personal information.
Market Dynamics
The main factor driving the growth of the diabetes injection pens market is the rapid increase of diabetes across the globe. For instance, according to a 2020 report by CDC approximately 34.2 million people were suffering from diabetes. The new cases of diabetes are high among non-Hispanic blacks than non-Hispanic whites and non-Hispanic Asians. Other factors such as injuries caused due to needle sticks and bacterial infections caused by regular usages of syringes are estimated to propel the market growth of the insulin injection pens market.
However, the abundance of insulin patches, and other safer substitute for insulin injection pens are the main restraining factors hindering the growth of the market.
This market is distributed in five regions that include North America, Europe, Asia-Pacific, Middle East, and Africa, and Latin America. Among these North America is estimated to hold a significant share of the diabetes injection pens market owing to the increasing rate of type-1 diabetes and the development of new, safer to use pens by key players in the region. For instance, according to the Americans with Disabilities Act (ADA), in 2018, approximately 1.25 million people were suffering from type 1 diabetes. ADA estimates that around 40,000 people get diagnosed with Type 1 diabetes every year. The diabetes injection pens market in the Asia Pacific is estimated to witness significant growth owing to the rising concerns among the patients and the development and expansion of healthcare sectors.
Competitive Analysis
Key players operating in the global diabetes injection pens market include Jiangsu Delfu Co., Dickinson and Company, Becton, Eli Lilly and Company, Biocon Ltd, AstraZeneca Plc, and Novo Nordisk A/S.
No comments:
Post a Comment